ReviewVaccine2017
Development of vaccines against Crimean-Congo haemorrhagic fever virus.
Review in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 95 citations in OpenAlex.
- Targeted cleavage site mutations in the Gn precursor enable efficient generation of replication-competent rVSV-based surrogates for emerging nairoviruses.Emerging microbes & infections · 2026Article
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- A case report and mini-review of Crimean-Congo hemorrhagic fever with encephalitis: an unexpected complication.Journal of neurovirology · 2025Review
- Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge.NPJ vaccines · 2025Article
- Article
- Mapping the potential suitable habitats for Hyalomma rufipes (Acari: Ixodidae) in Africa and Western Eurasia.PLoS neglected tropical diseases · 2025Article
- Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread.Science translational medicine · 2025Article
- Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Crimean-Congo haemorrhagic fever among healthcare workers in Iran 2000-2023, a report of National Reference Laboratory.BMC infectious diseases · 2024Article
- Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies.Pathogens (Basel, Switzerland) · 2024Review
- The Role of Nucleocapsid Protein (NP) in the Immunology of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).Viruses · 2024Review
- Exposure patterns and the risk factors of Crimean Congo hemorrhagic fever virus amongst humans, livestock and selected wild animals at the human/livestock/wildlife interface in Isiolo County, upper eastern Kenya.PLoS neglected tropical diseases · 2024Article
- Looking Beyond the Lens of Crimean-Congo Hemorrhagic Fever in Africa.Emerging infectious diseases · 2024Review
- Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges.Biological procedures online · 2024Review
- The Risk of Crimean Congo Haemorrhagic Fever in India as a Growing Health Concern.Infectious disorders drug targets · 2024Review
- Crimean-Congo haemorrhagic fever (CCHF): present and future therapeutic armamentarium.Le infezioni in medicina · 2024Review
- Outcome of the entomological monitoring for Crimean-Congo haemorrhagic fever virus in the western and southern regions of Kazakhstan in 2021-2022.Frontiers in epidemiology · 2024Article
- Cocktail vaccine for the management ofFrontiers in immunology · 2024Article
- Bunyavirales: Scientific Gaps and Prototype Pathogens for a Large and Diverse Group of Zoonotic Viruses.The Journal of infectious diseases · 2023Article
- Crimean-Congo haemorrhagic fever virus.Nature reviews. Microbiology · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo haemorrhagic fever virus (CCHFV) is a deadly human pathogen of the utmost seriousness being highly lethal causing devastating disease symptoms that result in intense and prolonged suffering to those infected. During the past 40years, this virus has repeatedly caused sporadic outbreaks responsible for relatively low numbers of human casualties, but with an alarming fatality rate of up to 80% in clinically infected patients. CCHFV is transmitted to humans by Hyalomma ticks and contact with the blood of viremic livestock, additionally cases of human-to-human transmission are not uncommon in nosocomial settings. The incidence of CCHF closely matches the geographical range of permissive ticks, which are widespread throughout Africa, Asia, the Middle East and Europe. As such, CCHFV is the most widespread tick-borne virus on earth. It is a concern that recent data shows the geographic distribution of Hyalomma ticks is expanding. Migratory birds are also disseminating Hyalomma ticks into more northerly parts of Europe thus potentially exposing naïve human populations to CCHFV. The virus has been imported into the UK on two occasions in the last five years with the first fatal case being confirmed in 2012. A licensed vaccine to CCHF is not available. In this review, we discuss the background and complications surrounding this limitation and examine the current status and recent advances in the development of vaccines against CCHFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.